Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma
A phase 1/2 trial of Vactosertib in osteosarcoma, run by MedPacto, Inc., now recruiting.
Overview
Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma is a phase 1/2 interventional study registered as NCT05588648 by MedPacto, Inc., with 48 participants planned, started 2023-05-01 and due to reach its primary completion in 2025-09. Interventions recorded: Vactosertib.
Setting
A Phase I/II, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib as a Single Agent in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma
Phase
Phase 1/2
Sponsor
MedPacto, Inc.
Registry
Enrolled
48
Similar pages
not linked directly; found by shared links- TrialLu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)
Shares Osteosarcoma and the tag pipeline.
- TreatmentCobolimab
Shares Osteosarcoma and the tag pipeline.
- TreatmentHS-20093
Shares Osteosarcoma and the tag pipeline.